This is an prospective, open label, multicenter study to evaluate the efficacy and safety of neoadjuvant serplulimab plus weekly paclitaxel and carboplatin in patients with triple-negative breast cancer.
Eligibility
Sex
FEMALE
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria:
* Female, Aged ≥18 and ≤70 years
* Histologically confirmed triple negative breast cancer (ER\<10%, PR\<10%, and HER2 negative)
* Subjects with at least one evaluable lesion
* ECOG 0-1
* Adequate organ function
Exclusion Criteria:
* Metastatic disease (Stage IV)
* Female patients who are pregnancy, lactation or women who are of childbearing potential tested positive in baseline pregnancy test;Female patients of childbearing age that are reluctant to take effective contraceptive measures throughout the trial period
Primary outcome measure(s)
Proportion of patients with pCR — 1-2 weeks after surgery Number of patients with pathological complete response/Number of all eligible patients
Trial sites (1)
Facility
City
Region
Status
Renji Hospital, School of Medicine, Shanghai Jiaotong University
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.